Investment Rating - The report maintains a "Buy" rating for the company, with a target price based on a closing price of 44.25 [1][8]. Core Insights - The company's Q3 revenue exceeded expectations, with a year-on-year growth of 53.20%, reaching 3.54 billion yuan. The net profit for Q3 was 591.2 million yuan, growing by 11.37% year-on-year [2][3]. - The company has significantly increased its R&D investment, with a total of 120 million yuan in R&D expenses for the first three quarters of 2024, representing a 43.76% increase year-on-year [2][3]. - The clinical business is expected to grow rapidly, contributing to new revenue streams, particularly through equity sharing as centralized procurement progresses [2][3]. Financial Performance Summary - For the first three quarters of 2024, the company achieved a total revenue of 917 million yuan, a 32.47% increase year-on-year, and a net profit of 208 million yuan, up 21.40% year-on-year [2][3]. - The company forecasts revenues of 1.24 billion yuan, 1.64 billion yuan, and 2.14 billion yuan for 2024, 2025, and 2026 respectively, with growth rates of 33.24%, 31.83%, and 30.89% [3]. - The projected net profits for the same years are 272 million yuan, 361 million yuan, and 475 million yuan, with growth rates of 47.33%, 32.66%, and 31.68% respectively [3]. R&D and Project Development - The company has initiated 117 new self-research projects, bringing the total to over 450, which includes innovative drugs, generic drugs, and modified new drugs across various disease areas [2][3]. - R&D expenses accounted for 13.04% of total revenue, an increase of 1.03 percentage points compared to the same period last year [2][3]. Market Position and Future Outlook - The company is positioned to outperform the market, with expectations of a relative increase in stock price of over 15% compared to the CSI 300 index in the next six months [8]. - The overall industry outlook is positive, with anticipated returns exceeding the CSI 300 index by more than 5% in the next six months [7].

证券代码：688621 证券简称：阳光诺和 北京阳光诺和药物研究股份有限公司 投资者关系活动记录表 （2024 年 10 月） | --- | --- | --- | |----------------|--------------------------|--------------------------------------------------| | | | | | | R | 特定对象调研 £分析师会议 | | 投资者关系活动 | □ 媒体采访 | £ 业绩说明会 | | | □ 新闻发布会 □路演活动 | | | 类别 | £ 现场参观 | | | | £ 其他（电话会议） | | | | | 广发证券、开源证券、德邦证券、浙商证券、兴业证 | | | | 券、财通证券、招商证券、中金证券、东北证券、国盛 | | | | 证券、长江证券、太平洋证券、国海证券、海通证券、 | | 参与单位名称 | | 光大证券、华西证券、中泰证券、华安证券、华福证 | | | | 券、中银证券、民生证券、国金证券、信达证券、东方 | | | | 证券、天风证券、方正证券、华创证券、宁银理财 | | 时间 | 2 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown rapid revenue growth in Q3, with a year-on-year increase of 53.20%, and a total revenue of 9.17 billion yuan for the first three quarters, representing a 32.47% increase year-on-year [4] - The company maintains a positive long-term growth outlook, with profit forecasts for 2024-2026 expected to be 274 million, 363 million, and 472 million yuan respectively, and corresponding EPS of 2.45, 3.24, and 4.22 yuan [4] - The company has a strong pipeline in drug research, with 117 new self-research projects initiated and 8 new drug projects approved for clinical trials as of mid-2024 [5] - The clinical trial and bioanalysis services have also seen significant growth, with a revenue increase of 50.28% year-on-year in H1 2024 [6] Financial Performance Summary - For Q3 2024, the company achieved a revenue of 3.54 billion yuan, with a net profit of 590 million yuan, reflecting a year-on-year growth of 11.37% [4] - The company's revenue for 2024 is projected to reach 1.198 billion yuan, with a year-on-year growth rate of 28.5% [7] - The gross profit margin is expected to be 53.8% in 2024, with a net profit margin of 22.9% [7] - The company's return on equity (ROE) is projected to be 21.1% in 2024, indicating strong profitability [7] Business Development - The pharmaceutical research business has shown steady growth, with a revenue of 343 million yuan in H1 2024, up 8.29% year-on-year [5] - The company has established four professional platforms for clinical trials and has partnered with over 260 hospitals for long-term clinical cooperation [6] - The company is focusing on the development of peptide and small nucleic acid drugs, with ongoing clinical trials for new drug projects [5]

证券时报e公司讯，10月29日，阳光诺和宣布：公司与北京艺妙神州医药科技有限公司（简称"艺妙神 州"）及其全资子公司厦门再妙生物科技有限公司（简称"再妙生物"）合作开发的用于治疗系统性红斑 狼疮（SystemicLupusErythematosus,SLE)的新一代CAR-T药物ZM001注射液（简称"ZM001"），获得国 家药品监督管理局颁发的《药物临床试验批准通知书》。 标志着阳光诺和正式进入生物创新药领域，在CAR-T细胞治疗自身免疫性疾病领域取得的重大突破。 ...

申请事项：境内生产药品注册临床试验 受理号：CXSL2400515 申请人：厦门再妙生物科技有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2024 年 8 月 2 日受理的 ZM001 注射液符合药品注册的有关要求，同意本品开展治疗 系统性红斑狼疮的临床试验。 二、药品的其他相关情况 证券代码：688621 证券简称：阳光诺和 公告编号：2024-050 北京阳光诺和药物研究股份有限公司 自愿披露关于 ZM001 注射液获得药物临床试验批准 通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、药品基本情况 药品名称：ZM001 注射液 SLE 是一种慢性的累及多器官的自身免疫性疾病，其发病机制为机体免疫失 衡引起自身抗原反应性 B 细胞的异常激活，不断产生自身抗体，导致免疫复合 物的形成，并引起全身炎症，损伤各种组织和器官。据估算，我国 SLE 患者约 有 100 万人，总数位居全球第一，发病率位居第二，临床治疗依赖于长期服用免 疫抑制剂和激素药物，已上市的靶向治疗药物疗效有限，仍有 ...

Financial Performance - The company's operating revenue for the third quarter reached ¥353,817,225.74, an increase of 53.20% compared to the same period last year[2] - The net profit attributable to shareholders was ¥59,117,260.75, reflecting an increase of 11.37% year-over-year[2] - The net profit after deducting non-recurring gains and losses was ¥58,748,468.19, up by 10.88% from the previous year[2] - The basic earnings per share for the quarter were ¥0.52, reflecting a growth of 10.64% year-over-year[2] - Total revenue for the first three quarters of 2024 reached CNY 916,680,884.20, a 32.6% increase from CNY 692,004,549.34 in the same period of 2023[15] - Operating profit for the first three quarters of 2024 was CNY 222,105,651.02, compared to CNY 183,469,944.29 in the previous year, reflecting a growth of 21%[15] - Net profit for the first three quarters of 2024 amounted to CNY 203,799,957.02, up from CNY 172,649,313.65 in 2023, indicating a 17.9% increase[15] - The net profit attributable to the parent company for Q3 2024 was ¥207,688,863.72, an increase of 21.4% compared to ¥171,076,571.46 in Q3 2023[16] Research and Development - Research and development expenses totaled ¥50,411,944.72 for the quarter, representing a significant increase of 69.38% year-over-year[3] - The ratio of R&D expenses to operating revenue was 14.25%, an increase of 1.36 percentage points compared to the same period last year[3] - Research and development expenses for the first three quarters of 2024 totaled CNY 119,505,040.45, compared to CNY 83,126,105.32 in the same period last year, representing a 43.7% increase[15] Assets and Liabilities - The total assets of the company at the end of the quarter were ¥2,078,137,217.37, an increase of 11.55% from the end of the previous year[3] - Total assets as of the end of the third quarter of 2024 were CNY 2,078,137,217.37, up from CNY 1,863,018,477.35 at the end of the same period in 2023, marking an increase of 11.5%[13] - Total liabilities increased to CNY 948,728,396.78 from CNY 805,759,613.78, reflecting a growth of 17.7% year-over-year[13] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥108,044,406.76, a substantial increase of 302.66% compared to the same period last year[2] - The net cash flow from operating activities for the first three quarters of 2024 was ¥108,044,406.76, significantly up from ¥26,832,765.69 in the same period of 2023[17] - The net cash flow from investing activities for the first three quarters of 2024 was -¥174,471,861.83, worsening from -¥86,391,579.31 in the same period of 2023[18] - The company reported a total cash inflow from financing activities of ¥370,384,477.09 in the first three quarters of 2024, compared to ¥273,463,290.24 in the same period of 2023, marking a growth of 35.5%[18] - The cash outflow for financing activities was ¥350,657,884.94 in the first three quarters of 2024, up from ¥223,575,009.68 in the same period of 2023, reflecting an increase of 56.8%[18] Shareholder Information - The company reported a total of 7,495 common shareholders at the end of the reporting period, with the largest shareholder holding 27.59% of the shares[9] - The total number of shares held by the top ten shareholders accounted for 45.89% of the total shares outstanding[9] Current Assets and Inventory - As of September 30, 2024, the company's total current assets amounted to approximately CNY 1.59 billion, an increase from CNY 1.36 billion at the end of 2023, representing a growth of about 16.8%[11] - The company's cash and cash equivalents decreased to CNY 644.23 million from CNY 690.93 million, a decline of approximately 6.8%[11] - Accounts receivable increased significantly to CNY 444.50 million, up from CNY 292.87 million, reflecting a growth of approximately 51.7%[11] - The company’s inventory increased slightly to CNY 15.38 million from CNY 14.41 million, a growth of about 6.8%[11] - The company’s contract assets rose to CNY 329.46 million, up from CNY 252.11 million, reflecting an increase of approximately 30.7%[11] Equity and Investments - The weighted average return on equity was 5.35%, showing an increase of 0.01 percentage points compared to the previous year[3] - The company's long-term equity investments rose to CNY 41 million from CNY 30 million, indicating a growth of approximately 36.7%[11] - The total equity attributable to shareholders reached CNY 1,130,916,430.47, up from CNY 1,040,012,428.09, reflecting an increase of 8.7%[13] Operational Strategy - The company plans to continue investing in innovative drug development and expanding its market presence, which has led to an increase in business orders[7] - The company has not reported any significant changes in its operational strategies or new product developments during the reporting period[10] - There were no significant changes in the shareholder structure or any new financing activities reported during the quarter[10] - The company did not report any net profit from mergers under common control for the current and previous periods[16] - The company has not adopted new accounting standards or interpretations that would affect the financial statements for the year[20]

北京阳光诺和药物研究股份有限公司 会计师事务所选聘制度 （2024年10月） 第一章 总则 第一条 规范北京阳光诺和药物研究股份有限公司（以下简称公司）对会计师事 务所选聘（含续聘、改聘，下同）的程序，根据《中华人民共和国公司法》《国有企 业、上市公司选聘会计师事务所管理办法》以及公司章程等有关规定，特制定本制度。 第二条 公司选聘对财务会计报告发表审计意见、出具审计报告、内部控制审计 业务的会计师事务所，需遵照本制度的规定。选聘其他专项审计业务的会计师事务所， 视重要性程度可参照本制度执行。 第三条 公司选聘会计师事务所应经董事会审计与风险委员会审核后，报经董事 会和股东大会审议。公司不得在董事会、股东大会审议前聘请会计师事务所开展审计 业务。 第四条 持有公司 5%以上股份的股东、控股股东及实际控制人不得在公司董事 会、股东大会审议前，向公司指定会计师事务所，不得干预审计与风险委员会独立履 行审核职责。 第二章 会计师事务所执业质量要求 第五条 公司选聘的会计师事务所应当具有良好的执业质量记录，应当为符合 《中华人民共和国证券法》规定的会计师事务所，并满足下列条件： （一）具有独立的法人资格，具备国家行业 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 北京阳光诺和药物研究股份有限公司（以下简称"公司"）已于 2024 年 10 月 29 日发布公司 2024 年第三季度报告，为便于广大投资者更全面深入地了解公 司 2024 年第三季度经营成果、财务状况，公司计划于 2024 年 12 月 02 日上午 11:00-12:00 举行 2024 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年第三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 会议召开时间：2024 年 12 月 02 日(星期一) 上午 11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 ...

证券代码：688621 证券简称：阳光诺和 公告编号：2024-048 北京阳光诺和药物研究股份有限公司 第二届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 北京阳光诺和药物研究股份有限公司（以下简称"公司"）于2024年10月28 日召开第二届监事会第十二次会议。本次会议通知于2024年10月25日以直接送 达、传真与邮件方式发出，会议由监事会主席王丹丹女士召集和主持，会议应出 席监事3名，实际出席监事3名，全部监事均参与表决所有议案。会议的召集和召 开符合《中华人民共和国公司法》（以下简称"《公司法》"）及《北京阳光诺 和药物研究股份有限公司章程》（以下简称"《公司章程》"）的规定。 二、监事会会议审议情况 经与会监事认真审议，一致通过如下决议： （一）审议通过《关于公司2024年三季度报告的议案》 1.公司 2024 年三季度报告的编制和审议程序符合法律法规、《公司章程》 及公司内部管理制度的各项规定； 2.公司 2024 年三季度报告的内容和格式符合中国证监会和 ...

证券代码：688621 证券简称：阳光诺和 公告编号：2024-047 北京阳光诺和药物研究股份有限公司 第二届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 北京阳光诺和药物研究股份有限公司（以下简称"公司"）于2024年10月28 日召开第二届董事会第十四次会议。本次会议通知于2024年10月25日以直接送 达、传真与邮件方式发出，会议由董事长利虔先生召集和主持，会议应出席董事 9名，实际出席董事9名，全部董事均参与表决所有议案，会议的召集和召开符合 《中华人民共和国公司法》（以下简称"《公司法》"）及《北京阳光诺和药物研究 股份有限公司章程》（以下简称"《公司章程》"）等法律、行政法规、部门规章、 规范性文件的规定。 二、董事会会议审议情况 经与会董事认真审议，一致通过如下决议： （一）审议通过《关于公司 2024 年三季度报告的议案》 公司2024年三季度报告的编制和审核程序符合法律、法规及《公司章程》、 公司内部管理制度的各项规定。公允地反映了公司2024年第三 ...